AN2 Therapeutics Inc’s recent filing unveils that its Chief Financial Officer Day Lucy unloaded Company’s shares for reported $3965.0 on Jan 03 ’25. In the deal valued at $1.34 per share,2,957 shares were sold. As a result of this transaction, Day Lucy now holds 32,670 shares worth roughly $41490.9.
Then, Chanda Sanjay sold 2,957 shares, generating $3,965 in total proceeds. Upon selling the shares at $1.34, the Chief Development Officer now owns 29,824 shares.
Before that, Prior Stephen David sold 2,029 shares. AN2 Therapeutics Inc shares valued at $2,721 were divested by the Chief Strategy Officer at a price of $1.34 per share. As a result of the transaction, Prior Stephen David now holds 33,313 shares, worth roughly $42307.51.
Leerink Partners downgraded its AN2 Therapeutics Inc [ANTX] rating to a Market perform from a an Outperform in a research note published on August 09, 2024; the price target was decreased to $1 from $5. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who decreased its forecast for the stock in early August from “an In-line” to “an Underperform”. Leerink Partners also remained covering ANTX and has increased its forecast on July 03, 2024 with a “an Outperform” recommendation from previously “Market perform” rating. JMP Securities revised its rating on April 02, 2024. It rated ANTX as “a Mkt outperform” which previously was an “a Mkt perform”.
Price Performance Review of ANTX
On Friday, AN2 Therapeutics Inc [NASDAQ:ANTX] saw its stock unchanged to $1.27. Over the last five days, the stock has gained 1.60%. AN2 Therapeutics Inc shares have fallen nearly -7.97% since the year began. Nevertheless, the stocks have fallen -93.91% over the past one year. While a 52-week high of $21.55 was reached on 01/06/25, a 52-week low of $0.87 was recorded on 01/15/25. SMA at 50 days reached $1.3087, while 200 days put it at $1.7293.
Levels Of Support And Resistance For ANTX Stock
The 24-hour chart illustrates a support level at 1.2567, which if violated will result in even more drops to 1.2433. On the upside, there is a resistance level at 1.2867. A further resistance level may holdings at 1.3033. The Relative Strength Index (RSI) on the 14-day chart is 44.52, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0632, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.26%. Stochastics %K at 19.57% indicates the stock is a buying.
How much short interest is there in AN2 Therapeutics Inc?
A steep rise in short interest was recorded in AN2 Therapeutics Inc stocks on 2024-10-31, dropping by 54906.0 shares to a total of 0.13 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.19 million shares. There was a decline of -41.11%, which implies that there is a negative sentiment for the stock.
